Background: The relationship between chronic rhinosinusitis (CRS) and airflow obstruction is still unclear. This cross-sectional study was conducted to investigate whether CRS is an independent risk factor for airflow obstruction in never-smokers without asthma.
Introduction
Chronic rhinosinusitis (CRS) is characterized by mucosal inflammation affecting both the nasal cavity and paranasal sinuses [1, 2] . CRS is one of the most common chronic upper respiratory tract conditions associated with chronic lower respiratory tract diseases such as prolonged and chronic cough, chronic bronchitis, cystic fibrosis, bronchiectasis, and asthma [1] [2] [3] [4] [5] [6] [7] .
Chronic obstructive pulmonary disease (COPD) is characterized by airflow obstruction and pulmonary hyperinflation [8] . Cigarette smoke is the most important risk factor for development of COPD, but recently evidence of COPD in nonsmokers has been accumulating [9] [10] [11] [12] . It is well known that a high proportion of patients with COPD have CRS as a comorbidity [13] [14] [15] [16] . Asthma is an important factor related to the development of COPD in individuals who have never smoked [3] [4] [5] [6] [7] . However, the correlation between the presence of CRS and COPD in never-smokers without asthma is still unclear. Here we conducted a cross-sectional study to clarify whether CRS is an independent risk factor for airflow obstruction in never-smokers.
Methods

Ethical approval
The present study was conducted in accordance with good clinical practice guidelines and the declaration of Helsinki, and approved by the ethics committee of Fukuoka Sanno Hospital (no. FS-79, September 27 th , 2012). Each investigator obtained written informed consent from all patients.
Subjects
Subjects aged ≥ 40 yr without asthma who presented at Fukuoka Sanno Hospital, Fukuoka, Japan, between October 2012 and June 2014 were recruited. Subjects who had a history of COPD and other chronic lower respiratory tract diseases, moderate to severe diseases of other organs such as heart failure, liver cirrhosis, renal failure, and cerebrovascular disease, or with active malignancies, were excluded. Subjects for whom flow-volume curves obtained by spirometry were inconclusive were also excluded. Patients with eosinophilic CRS. usually have bronchial asthma and peripheral eosinophilia. To remove any patients with asthma and/or eosinophilic CRS. Those with blood eosinophil counts of >600/mm 3 were excluded. Among our patients, 5, 6, 4, 1, and 17 received inhaled corticosteroids and long acting bronchodilators, anti-allergic agents, cystinyl leukotriene antagonists, macrolide antibiotics, and mucolytic agents, respectively, and none received intranasal or oral corticosteroids. However, all medications were washed out for at least 4 weeks after informed consent had been obtained.
Diagnosis of CRS and its severity
Diagnosis of CRS was based on symptoms such as nasal obstruction and discharge, discolored postnasal purulence and discharge, hyposmia or anosmia, and facial pain and pressure, which had persisted for >3 months. The features of sinuses revealed by facial computed tomography (CT) were also referred for diagnosis. Definitive diagnosis of CRS and nasal polyp was based on the opinions of two independent otolaryngologists.
The severity of CRS was based on the Lund-Mackay score, which ranges from 0 (complete lucency of all sinuses) to 24 (complete opacity of all sinuses) on facial CT [17] . Scores of 0 to 2 were rated as normal, and scores of 7 to 24 were rated as CRS. Patients with scores of 3 to 6 were excluded from the final analysis. The findings of facial and chest CT were interpreted by two independent radiologists.
Study design
This study had a cross-sectional design. After providing written informed consent, each subject was required to give medical information about symptoms, medication, smoking habits and smoking index (pack * yr) and comorbidities, and then blood tests, chest radiography, facial and chest CT, and spirometry were performed. Each subject was also required to meet the chest physicians and otolaryngologists after the examinations. None of the subjects were administered bronchodilators for spirometry.
Blood tests
Peripheral blood counts were measured using an automatic flow cytometry system (XE-5000, Sysmex co., Tokyo, Japan). Serum total IgE levels were measured using commercial fluorenzymeimmunoassay kits (SRL Inc., Tokyo, Japan). However, the serum specific IgE levels were not examined, as we were unable to obtain informed consent from all of the enrolled patients.
Spirometry
Spirometry was performed three times using an electronic spirometer (SP-770COPD, Fukuda Denshi, Tokyo, Japan) in accordance with the ATS/ERS task force document [18] , and the best values of forced vital capacity (FVC) and forced expiratory volume in 1 second (FEV 1 ) were accepted. The diagnosis and severity of airflow obstruction were based on a FEV 1 /FVC ratio of <0.7 and the classification of the Global Initiative for Chronic Obstructive Lung Disease (GOLD) [7] , respectively. We used the Japanese Respiratory Society (JRS) survey reference equations for Japanese men and women to calculate the predicted pulmonary function values [19] . The lower limit of the normal (LLN) threshold of the FEV 1 /FVC ratio was also evaluated as the lower fifth percentile of the predicted value (<LLN) based on the JRS survey for defining airflow obstruction [11, 12, 19] .
Statistical analysis
The subjects were divided into 4 groups: never-smokers with CRS, smokers with CRS, never-smokers without CRS, and smokers without CRS. All the data were expressed as mean ± standard deviation (SD). The characteristics of the subjects were compared using Student's t test and χ 2 test. The risk ratios [95% confidence interval (CI)] for CRS based on airflow obstruction were assessed using univariate and multivariate analyses. The correlations (r) between predicted %FEV 1 and the severity of chronic sinusitis, age, and smoking index were analyzed by nonparametric Spearman's test. Differences at p<0.05
Figure 1: Study design
Written informed consent was obtained from 228 subjects aged ≥ 40 yr without asthma. Six subjects with bronchiectasis were excluded, as were 15 for whom data on smoking history were unavailable. Fourteen patients with blood eosinophil counts of >600/mm 3 were also excluded. Thirty-five subjects who were not definitively diagnosed as having CRS or normal sinus were also excluded.
CRS: Chronic Rhinosinusitis, LLN: Lower Limit of Normal, FEV 1 : Forced Expiratory Volume in 1 second, FVC: Forced Vital Capacity were considered statistically significant. All analyses were performed using the statistical software package JMP version 9.0 ® (SAS Institute Japan Inc., Tokyo, Japan).
Results
Characteristics of the subjects
As shown in figure 1, 228 subjects aged ≥ 40 yr without asthma were enrolled. However, six subjects with bronchiectasis defined by chest CT were excluded, as were 15 subjects who did not provide details of their smoking history. Fourteen subjects with blood eosinophil counts of >600/mm 3 were also excluded. An additional 35 subjects were excluded because a definitive diagnosis of CRS and normal sinus could not be obtained. Thus, 158 subjects were finally analyzed. The numbers (%) of subjects with and without definitive CRS were 49 (31.0) and 109 (69.0), respectively. There were 22 neversmokers with CRS, 27 smokers with CRS, 69 never-smokers without CRS, and 40 smokers without CRS. Table 1 shows the characteristics of the subjects. Males accounted for a significantly higher proportion of smokers with and without CRS than among never-smokers. Five (22.7%) never-smokers and 3 (11.1%) smokers with CRS had nasal polyps. Smokers with CRS had a significantly lower FEV 1 /FVC ratio than never-smokers with CRS (p=0.0273) or never-smokers without CRS (p<0.001). Smokers without CRS had a significantly lower FEV 1 /FVC ratio than neversmokers without CRS (p=0.0153).
The proportion (%, p value) of never-smokers with CRS [5 (22.7%, p=0.0265)] who had a FEV 1 /FVC ratio of <0.7 was significantly higher than that of never-smokers without CRS [3 (4.3%)], whereas there was no difference in the proportion of <LLN patients between these two groups [4 (18.2%) and 3 (4.3%), respectively] (p=0.0967). Among 4%, p=0.3422) , respectively] and non-CRS [11 (27.5%) and 12 (30.0%), respectively] groups. The numbers of subjects who had a stage II or more severe GOLD classification with a FEV 1 /FVC ratio of <0.7 and <LLN were 5 and 4 for never-smokers with CRS, 9 and 10 for smokers with CRS, 3 and 3 for never-smokers without CRS, and 9 and 10 for smokers without CRS, respectively ( Table 1 ).
The subjects with CRS had significantly higher blood eosinophil counts than those without CRS (p<0.0001). In never-smokers and smokers, there was no significant correlation between blood eosinophil counts and %FEV 1 
Multivariate analysis of risk factors for airflow obstruction
Multivariate analysis showed that the adjusted risk ratios (95%CI, p value) for the presence of CRS were 2.65 (1.09-6.53, p<0.05) for patients aged ≥ 70 yr, 3.45 (1.22-9.74, p<0.05) for male patients, 1.86 (Table 3) .
Correlation between Lund-Mackay scores for CRS and airflow obstruction
The Lund-Mackay scores for CRS were significantly associated with the FEV 1 /FVC ratio (r= 
Discussion
In this Japanese cohort, we have demonstrated that the presence of CRS is an independent risk factor for development of airflow obstruction in never-smokers aged ≥ 40 yr without asthma. Another recent Japanese study also showed that CRS patients had significant airflow obstruction regardless of the presence of asthma [7] . In our present study, about 30% of the 158 subjects with prolonged cough had a definitive diagnosis of CRS. We considered airflow obstruction to be present in patients who had a FEV 1 /FVC ratio of <0.7 and <LLN. Seventeen (34.7%) and 16 (32.7%) of the 49 subjects with CRS had a FEV 1 /FVC ratio of <0.7 and <LLN, respectively. Thirty (19.0%) and 31 (19.6%) of the 158 subjects had a FEV 1 /FVC ratio of <0.7 and <LLN, respectively, without administration of bronchodilators. Among never-smokers and smokers with CRS, 5 (22.7%) and 4 (18.2%), respectively, had airflow obstruction based on a FEV 1 /FVC ratio of <0.7 and <LLN. All of the never-smokers evaluated as having airflow obstruction based on both of the latter criteria were GOLD stage II. The different results obtained using these two criteria were statistically close. Previous studies had demonstrated that 2-8% of never-smokers in the general Japanese population had airflow obstruction [20] [21] [22] . Although the data were not directly comparable, the proportion of never-smokers with CRS who had airflow obstruction in our study was higher than that in the general population. Although the presence of nasal polyps might be one of the risk factors for airflow obstruction [19] , this was not the case in the present study because the proportion of subjects with nasal polyps was small. It is well known that CRS with nasal polyps is associated with asthma and adverse reactions to aspirin and other non-steroidal anti-inflammatory drugs that inhibit cyclooxygenase-1. Therefore, CRS with nasal polyps is thought to be mainly characterized by eosinophilic inflammation and prevalent Th2 responses including release of IL-5, but not neutrophilic types of CRS [23] . Thus there may be differences between eosinophilic or neutrophilic CRS and with airflow obstructions, and further analysis will be needed to clarify this issue.
We also found that the severity of CRS was significantly associated with the FEV 1 /FVC ratio in never-smokers, whereas in smokers the severity was significantly associated with predicted %FEV 1 . In addition, multivariate analysis showed that the presence of CRS, smoking history, and higher age were independent risk factors for airflow obstruction.
Interaction between asthma and CRS has been well documented in previous studies [24, 25] . In the present study, we carefully excluded subjects with chronic lower respiratory diseases associated with CRS, such as asthma, bronchiectasis and interstitial pneumonia. Using chest CT, our two independent radiologists found signs of bronchiectasis in 6 patients. None of the subjects had interstitial pneumonia, but emphysematous changes were evident in some smokers. Our results demonstrated that never-smokers with CRS included a significantly higher proportion (2.46-to 2.65-fold) of individuals with airflow obstruction than never-smokers without CRS.
The study had some limitations. First, although all of the subjects had normal chest CT findings, pathohistological features in the bronchi and bronchioles were not assessed. In order to investigate the interactions between airflow obstruction and CRS, it will be necessary to study airway inflammation and hyperresponsiveness, and the reversibility of airway obstruction after administration of bronchodilators. In this study we demonstrated that subjects with CRS, both never-smokers and smokers, had significantly higher peripheral eosinophil counts than subjects without CRS, even though we excluded patients with asthma via interview and determination of blood eosinophil counts (>600/mm 3 ). Second, interactions between CRS symptoms, rhinorrhea inflammation, and airway obstruction remained unclear [26] . Third, we did not investigate whether control of CRS would improve airflow obstruction. Further intervention trials will therefore be necessary to clarify these issues.
In summary, the present study has shown that CRS is an independent risk factor for development of airflow obstruction, and that the severity of CRS is significantly associated with airflow obstruction in never-smokers. We believe that, at least in Japanese patients, the presence of CRS contributes to chronic obstructive pulmonary disease in never-smokers. 
